|
Nextcure, Inc. (NXTC) Valeure DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
NextCure, Inc. (NXTC) Bundle
Évaluez les perspectives financières de Nextcure, Inc. (NXTC) comme un expert! Cette calculatrice DCF (NXTC) est livrée avec des données financières pré-remplies et offre une flexibilité totale pour modifier la croissance des revenus, le WACC, les marges et autres hypothèses essentielles en fonction de vos projections.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.3 | 22.4 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 252.58 | -100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -34.8 | -37.8 | -65.0 | -70.3 | -59.0 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | -548.2 | -168.97 | 100 | 100 | 100 | 20 | 20 | 20 | 20 | 20 |
| Depreciation | 2.7 | 3.4 | 4.3 | 4.5 | 3.7 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 42.35 | 15.25 | 100 | 100 | 100 | 71.52 | 71.52 | 71.52 | 71.52 | 71.52 |
| EBIT | -37.5 | -41.2 | -69.3 | -74.7 | -62.7 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | -590.55 | -184.22 | 100 | 100 | 100 | 20 | 20 | 20 | 20 | 20 |
| Total Cash | 334.6 | 283.4 | 219.6 | 159.9 | 108.3 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 0 | 0 | 100 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
| Inventories | .0 | .0 | .0 | -.7 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0 | 0 | 100 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
| Accounts Payable | 1.9 | 3.9 | 1.9 | 4.3 | 2.3 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 29.32 | 17.43 | 100 | 100 | 100 | 69.35 | 69.35 | 69.35 | 69.35 | 69.35 |
| Capital Expenditure | -3.4 | -7.1 | -2.4 | -2.1 | -.8 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | -53.11 | -31.87 | 100 | 100 | 100 | -17 | -17 | -17 | -17 | -17 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -37.5 | -37.4 | -69.3 | -69.4 | -62.7 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -36.3 | -39.1 | -69.3 | -64.0 | -62.5 | -2.3 | .0 | .0 | .0 | .0 |
| WACC, % | 6.43 | 6.34 | 6.43 | 6.37 | 6.43 | 6.4 | 6.4 | 6.4 | 6.4 | 6.4 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -2 | |||||||||
| Net Debt | -6 | |||||||||
| Equity Value | 4 | |||||||||
| Diluted Shares Outstanding, MM | 28 | |||||||||
| Equity Value Per Share | 0.15 |
What You Will Get
- Real NextCure Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on NextCure’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- Pre-Loaded Data: NextCure, Inc.'s historical financial statements and pre-filled forecasts.
- Fully Adjustable Inputs: Edit WACC, tax rates, revenue growth, and EBITDA margins.
- Instant Results: See NextCure, Inc.'s intrinsic value recalculate in real time.
- Clear Visual Outputs: Dashboard charts display valuation results and key metrics.
- Built for Accuracy: A professional tool for analysts, investors, and finance experts.
How It Works
- Download: Obtain the pre-built Excel file containing NextCure, Inc.'s (NXTC) financial data.
- Customize: Modify projections, including revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various projections and instantly compare results.
- Make Decisions: Leverage the valuation findings to inform your investment strategy.
Why Choose This Calculator?
- Accurate Data: Real NextCure, Inc. (NXTC) financials ensure reliable valuation results.
- Customizable: Adjust key parameters like growth rates, WACC, and tax rates to match your projections.
- Time-Saving: Pre-built calculations eliminate the need to start from scratch.
- Professional-Grade Tool: Designed for investors, analysts, and consultants.
- User-Friendly: Intuitive layout and step-by-step instructions make it easy for all users.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and accurate valuation models for analyzing NextCure, Inc. (NXTC) within their portfolios.
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions regarding NextCure, Inc. (NXTC).
- Consultants and Advisors: Deliver precise valuation insights for clients interested in NextCure, Inc. (NXTC) stock.
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling with a focus on NextCure, Inc. (NXTC).
- Biotech Enthusiasts: Gain insights into how biotech firms like NextCure, Inc. (NXTC) are valued in the investment landscape.
What the Template Contains
- Preloaded NXTC Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.